Compare Duke Energy Corp (DUK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs TG Therapeutics Inc — how do they compare? Duke Energy Corp trades at $123 (market cap $96.05B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Duke Energy Corp is far larger — about 12.6× TG Therapeutics Inc's market cap, and Duke Energy Corp pays a 3.52% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DUK | TGTX | |
|---|---|---|
Market Cap | $96.05B | $7.64B |
Sector | Utilities | Health |
52-Week High | $133.46 | $59.06 |
52-Week Low | $113.99 | $26.94 |
Enterprise Value | $188.56B | $7.84B |
Dividend Yield | 3.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $123.23, up 1.68% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.43 exceeding expectations, supported by growing revenue and healthy profit margins. Recent news highlights operational challenges from storms affecting customers but also strategic initiatives including a $35 million equity units offering and data center growth opportunities.
The outlook remains stable with analyst consensus pointing to upside potential (target $136.17) and no sell ratings. Key risks include regulatory scrutiny and capital expenditure pressures, but the company's dividend reliability and infrastructure investments provide long-term stability. The stock presents a balanced opportunity for income-focused investors amid current technical weakness.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
